MULTIPLE MYELOMA

Decision-making for the second to fourth lines of therapy in multiple myeloma can depend on many factors, and clinicians still face unanswered questions, according to Krina K. Patel, MD, MSc.

In an interview with Targeted Oncology, Paul Richardson, MD, discussed the outcome of the ODAC meeting and provided his personal insights on what may be next for melphalan flufenamide.

Due to the potential detriment in overall survival, its failure to demonstrate a progression-free survival benefit, and the lack of a known appropriate dose, ODAC has voted that melphalan flufenamide is not favorable in relapsed/refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Cristina Gasparetto, MD, discussed data supporting the use of selinxor for patients with relapsed/refractory multiple myeloma.

Adam Cohen, MD, discusses the current FDA-approved BCMA-directed therapies in the multiple myeloma space and the clinical data supporting each agent.

The phase 2 MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone demonstrates the promise of minimal residual disease surveillance in newly diagnosed multiple myeloma with 0 or 1 high-risk cytogenetic abnormalities

During a live virtual event, Brea C. Lipe, MD, discussed what considerations affect the choice of triplet or quadruplet therapy for a patient with transplant-eligible multiple myeloma.

The CoMMpass genomic data set of patients with multiple myeloma was utilized by investigators, contributing to 19 abstracts reported at the International Myeloma Society.

The phase 2 CARTITUDE study showed encouraging response in the heavily-pretreated multiple myeloma population. Now, the phase 3 CARTITUDE-4 trial is underway.

An association between biallelic deletion of TNFRSF17 and resistance to therapies like chimeric antigen receptor T cells and T-cell engagers has been identified in myeloma.

The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.

Results of a phase 1 trial of the bispecific antibody ABBV-383 showed a high overall response rate and manageable adverse event profile in patients with relapsed/refractory multiple myeloma.

Results shown from studies of bispecific antibodies, immunomodulatory drugs , and antibody-drug conjugates signal a bright future for relapsed or refractory myeloma treatment.

No significant survival differences were shown between 2 high-dose regimens for newly diagnosed multiple myeloma. However, certain prognostic factors may improve or decrease survival.

Patients with relapsed or refractory multiple myeloma who relapsed after treatment with B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy.

Final overall survival in the ICARIA-MM study favored the combination of Isatuximab-irfc plus pomalidomide and low-dose dexamethasone.

Updated analysis results of from the IKEMA showed improvement in the depth of response to isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma.

In LINKER-MM1 study, responses to REGN5458 occurred early, were durable, and deepened over time.

Post-hoc analysis findings from phase 2 DREAMM-2 trial show no relationship between ocular conditions found at baseline in patients with relapsed or refractory multiple myeloma and ocular toxicity from belantamab mafodotin.

Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.

Data presented at the 19th International Myeloma Society Annual Meeting show that carfilzomib plus lenalidomide and dexamethasone after transplant prolongs progression-free survival compared with lenalidomide alone in patients with myeloma.

A study of real-world outcomes of patient with relapsed or refractory multiple myeloma treated with isatuximab in now enrolling.

Patients with treatment-naive myeloma treated with humanized IgGx CD38-targeted monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone for at least 18 months had a overall survival benefit in the phase 3 MAIA study.

Updated analysis of the IKEMA trial showed the combination of isatuximab, carfilzomib, and dexamethasone to elicit superior progression-free survival vs carfilzomib and dexamethasone alone in patients with multiple myeloma.

Findings from the phase 3 DETERMINATION trial show lenalidomide plus bortezomib, dexamethasone, and autologous stem cell transplantation to improve progression-free survival in patients with multiple myeloma.